Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Financial Performance and Results of Operations
BSX logo

Boston Scientific Sales Surge 20% on Innovation and Acquisitions

BSX10-QFiling Date: 11/3/2025
Boston Scientific Corporation
Description

What this story covers

Boston Scientific's Q3 2025 10-Q highlights 20% net sales growth to $5.1B, driven by cardiovascular and MedSurg segments, bolstered by acquisitions like Bolt Medical and SoniVie. Strong cash flow of $3.2B supports $11.6B debt, with margins improving amid R&D investments. Risks include supply chains and regulations, but overall resilience shines.

Story snapshot

CompanyBoston Scientific Corporation
TickerBSX
VariantStandard detailed
Duration9:50
Filing type10-Q
PeriodQ3 2025
IndustryHealthcare & Pharmaceuticals
Accession0000885725-25-000050

Full Story Script

Content not available for this story.

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in